14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Monday, 6th May 2024 MDGL stock ended at $235.57. This is 2.49% more than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 3.58% from a day low at $228.48 to a day high of $236.65.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Dec 11, 2023 $211.27 $212.97 $202.97 $210.43 381 655
Dec 08, 2023 $226.00 $227.94 $194.88 $208.32 1 001 994
Dec 07, 2023 $237.88 $241.50 $235.37 $235.61 320 778
Dec 06, 2023 $237.24 $244.99 $232.01 $236.71 408 382
Dec 05, 2023 $222.00 $237.10 $221.10 $235.11 466 517
Dec 04, 2023 $208.86 $222.03 $208.52 $221.98 392 389
Dec 01, 2023 $201.74 $213.54 $196.00 $213.12 411 751
Nov 30, 2023 $201.00 $208.49 $200.34 $203.30 321 794
Nov 29, 2023 $191.00 $200.33 $191.00 $197.36 357 164
Nov 28, 2023 $196.30 $196.30 $187.57 $190.94 230 702
Nov 27, 2023 $194.51 $197.88 $190.62 $197.30 269 281
Nov 24, 2023 $187.12 $200.69 $187.07 $195.56 182 101
Nov 22, 2023 $192.37 $196.23 $186.56 $190.48 243 069
Nov 21, 2023 $186.25 $190.98 $182.34 $188.44 345 284
Nov 20, 2023 $176.30 $190.63 $175.84 $190.05 559 839
Nov 17, 2023 $170.00 $176.84 $166.00 $176.66 506 926
Nov 16, 2023 $168.52 $170.97 $160.15 $168.69 443 815
Nov 15, 2023 $156.47 $175.39 $154.81 $161.68 808 314
Nov 14, 2023 $153.64 $156.83 $151.01 $156.47 478 171
Nov 13, 2023 $138.89 $146.99 $135.58 $146.00 374 120
Nov 10, 2023 $138.12 $139.46 $134.90 $138.84 278 071
Nov 09, 2023 $143.55 $144.71 $133.99 $136.35 354 073
Nov 08, 2023 $151.82 $152.43 $142.17 $143.37 468 973
Nov 07, 2023 $147.47 $154.04 $147.47 $152.11 473 813
Nov 06, 2023 $143.36 $147.90 $141.85 $147.37 370 179
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT